Shijiazhuang Keren Medical Technology Co., Ltd.

Primary objective: To study the pharmacokinetics of RHYK2008 (specification: 10 mg; experimental drug) developed by Shijiazhuang Keren Pharmaceutical Technology Co., Ltd. in healthy subjects under fasting conditions, using Lercanidipine Hydrochloride Tablets (trade name: Zanidip®; specification: 10 mg) owned by Recordati S.P.A. as the control drug, to provide a basis for subsequent clinical trials. Secondary objective: To observe the safety of fasting oral administration of experimental drugs and control drugs in healthy subjects.

Primary objective: To study the pharmacokinetics of clofazodone glucamine soft capsules (trade name: Vyndaqel®; specification: 20 mg (calculated as C14H7Cl2NO3.C7H17NO5)) held by Pfizer Europe MA EEIG as the reference preparation and clofazodone glucamine soft capsules (specification: 20 mg (calculated as C14H7Cl2NO3.C7H17NO5)) produced by Shijiazhuang Keren Pharmaceutical Technology Co., Ltd. as the test preparation in healthy subjects under fasting and postprandial conditions, and to evaluate whether the two preparations are bioequivalent. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.